Valneva SE (VALN) stock
VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.65−0.01 (-0.18%)
Close on Nov 16, 2026Market cap $490.25MP/E –Yield –
Valneva r&d expenses
Research and development expenses are spending on new products and technology.
Valneva's R&D Expenses for the twelve months ending Jun 30, 2026 was €83.10M, up 8.1% year over year. For fiscal 2025 it was €85.30M, up 15.1% from the year before. The highest annual figure on record is €173.28M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €85.30M | +15.1% |
| FY2024 | Dec 31, 2024 | €74.14M | +23.8% |
| FY2023 | Dec 31, 2023 | €59.89M | -42.9% |
| FY2022 | Dec 31, 2022 | €104.92M | -39.5% |
| FY2021 | Dec 31, 2021 | €173.28M | +105.2% |
| FY2020 | Dec 31, 2020 | €84.45M | +122.1% |
| FY2019 | Dec 31, 2019 | €38.02M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €15.02M | -14.1% |
| Q1 FY2026 | Mar 31, 2026 | €15.22M | +1.8% |
| Q4 FY2025 | Dec 31, 2025 | €25.57M | -0.0% |
| Q3 FY2025 | Sep 30, 2025 | €27.29M | +44.5% |
| Q2 FY2025 | Jun 30, 2025 | €17.49M | +5.7% |
| Q1 FY2025 | Mar 31, 2025 | €14.95M | +13.9% |
| Q4 FY2024 | Dec 31, 2024 | €25.58M | +44.7% |
| Q3 FY2024 | Sep 30, 2024 | €18.88M | +16.3% |
| Q2 FY2024 | Jun 30, 2024 | €16.55M | +38.9% |
| Q1 FY2024 | Mar 31, 2024 | €13.13M | -6.6% |
| Q4 FY2023 | Dec 31, 2023 | €17.67M | -40.2% |
| Q3 FY2023 | Sep 30, 2023 | €16.24M | -30.9% |
| Q2 FY2023 | Jun 30, 2023 | €11.91M | -61.8% |
| Q1 FY2023 | Mar 31, 2023 | €14.07M | -32.0% |
| Q4 FY2022 | Dec 31, 2022 | €29.54M | -47.3% |
| Q3 FY2022 | Sep 30, 2022 | €23.50M | -39.0% |
| Q2 FY2022 | Jun 30, 2022 | €31.19M | -38.8% |
| Q1 FY2022 | Mar 31, 2022 | €20.69M | -25.4% |
| Q4 FY2021 | Dec 31, 2021 | €56.05M | – |
| Q3 FY2021 | Sep 30, 2021 | €38.50M | – |
| Q2 FY2021 | Jun 30, 2021 | €51.01M | – |
| Q1 FY2021 | Mar 31, 2021 | €27.73M | – |
See a number that looks wrong?